Who says we will no longer Feel the Bern just because the New York native is out of the running for president?
A tweet from Senator Bernie Sanders’ account that went out to his 2.65 million followers on Friday sent pharmaceutical firm Ariad’s share price into a downward spiral.
Drug corporations' greed is unbelievable. Ariad has raised the price of a leukemia drug to almost $199,000 a year. https://t.co/EB4nEPxP2G
— Bernie Sanders (@SenSanders) October 14, 2016
“Europe's leading digital technology conference”
It's happening, Join 15k digital minds to shape what's next for your business
Following the tweet from Sanders’ account on Friday afternoon about how Ariad raised the price of a cancer drug, the company’s shares plummeted 15 percent, costing investors $387 million.
Interestingly, the tweet wasn’t signed with a “-B,” which indicates that it was written by a staffer and not by Bernie himself.
Bloomberg noted that Ariad has raised the wholesale acquisition price of its leukemia drug Iclusig four times this year: A 30-day pill pack now costs more than $16,000, amounting to $199,000 a year.
In addition to highlighting how greedy pharma companies can be, Sanders’ tweet also shows the incredible power of Twitter as a platform. It strikes me as rather odd that the company is finding it difficult to stay afloat on its own or secure a buyer. Of course, those issues are more closely tied to its ability to grow and monetize its service than to how relevant it is – but if a single tweet can cost roughly $400 million, there’s clearly plenty of value in Twitter yet.